Literature DB >> 26815785

[Orofacial pain - Trigeminal neuralgia and posttraumatic trigeminal neuropathy: Common features and differences].

V Thieme1.   

Abstract

Neuropathic pain is the result of a lesion or disease of the somatosensory system in the peripheral or central nervous system. Classical trigeminal neuralgia and posttraumatic trigeminal neuropathy are pain disorders which oral and maxillofacial surgeons and dentists are confronted with in the differential diagnostics in routine daily practice. The etiopathogenesis of classical trigeminal neuralgia is attributable to pathological blood vessel-nerve contact in the trigeminal nerve root entry zone to the brain stem. The typical pain symptoms are characterized by sudden stabbing pain attacks. The pharmaceutical prophylaxis is based on the individually titrated administration of anticonvulsant drugs. The indications for interventional treatment are dependent on the course, response to drug treatment, resilience and wishes of the patient. The neuropathic mechanism of posttraumatic trigeminal neuropathy originates from nerve damage, which leads to peripheral and central sensitization with lowering of the pain threshold and multiple somatosensory disorders. The prophylaxis consists of avoidance of excessive acute and long-lasting pain stimuli. Against the background of the biopsychosocial pain model, the treatment of posttraumatic trigeminal neuropathy necessitates a multimodal, interdisciplinary concept.

Entities:  

Keywords:  Biopsychosocial model; Chronic pain; Facial pain; Multimodal treatment; Neuropathic pain

Mesh:

Substances:

Year:  2016        PMID: 26815785     DOI: 10.1007/s00482-016-0097-6

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  55 in total

Review 1.  Molecular mechanisms of nociception.

Authors:  D Julius; A I Basbaum
Journal:  Nature       Date:  2001-09-13       Impact factor: 49.962

Review 2.  Frequency of nonodontogenic pain after endodontic therapy: a systematic review and meta-analysis.

Authors:  Donald R Nixdorf; Estephan J Moana-Filho; Alan S Law; Lisa A McGuire; James S Hodges; Mike T John
Journal:  J Endod       Date:  2010-09       Impact factor: 4.171

3.  Cyberknife radiosurgery in treating trigeminal neuralgia.

Authors:  Bryan M Lazzara; Orlando Ortiz; Ritu Bordia; Matthew R Witten; Jonathan A Haas; Alan J Katz; Jeffrey A Brown
Journal:  J Neurointerv Surg       Date:  2012-01-25       Impact factor: 5.836

4.  Drugs for neuropathic pain.

Authors:  Eija Kalso; D J Aldington; R A Moore
Journal:  BMJ       Date:  2013-12-19

Review 5.  Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment.

Authors:  Ralf Baron; Andreas Binder; Gunnar Wasner
Journal:  Lancet Neurol       Date:  2010-08       Impact factor: 44.182

Review 6.  [Recommendations of the updated LONTS guidelines. Long-term opioid therapy for chronic noncancer pain].

Authors:  W Häuser; F Bock; P Engeser; G Hege-Scheuing; M Hüppe; G Lindena; C Maier; H Norda; L Radbruch; R Sabatowski; M Schäfer; M Schiltenwolf; M Schuler; H Sorgatz; T Tölle; A Willweber-Strumpf; F Petzke
Journal:  Schmerz       Date:  2015-02       Impact factor: 1.107

7.  [Neurosurgical therapy of facial neuralgias].

Authors:  V M Tronnier; D Rasche; J Hamer; S Kunze
Journal:  Schmerz       Date:  2002-09       Impact factor: 1.107

8.  Development and validation of classification criteria for idiopathic orofacial pain for use in population-based studies.

Authors:  Vishal R Aggarwal; John McBeth; Mark Lunt; Joanna M Zakrzewska; Gary J Macfarlane
Journal:  J Orofac Pain       Date:  2007

9.  Screening for psychosocial risk factors in patients with chronic orofacial pain: recent advances.

Authors:  Judith A Turner; Samuel F Dworkin
Journal:  J Am Dent Assoc       Date:  2004-08       Impact factor: 3.634

10.  Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia.

Authors:  M Obermann; M-S Yoon; D Ese; M Maschke; H Kaube; H-C Diener; Z Katsarava
Journal:  Neurology       Date:  2007-08-28       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.